Tag
The POWER trial assessed a self-directed lifestyle program for patients with OSA and obesity, finding modest improvements in sleep-related quality of life but limited clinically meaningful weight loss over 12 months.
Recent substantial preoperative weight loss (>10%) in obese patients undergoing reduction mammoplasty is associated with increased surgical site infections and hospital readmissions compared to weight-stable obese patients, highlighting
Setmelanotide, an MC4R agonist, improves metabolic parameters and reduces metabolic syndrome severity in patients with POMC or LEPR deficiencies causing severe obesity, after one year of treatment.
This review synthesizes evidence from large cohort studies and meta-analyses highlighting bariatric surgery’s association with reduced risks of many obesity-related cancers, consistent across age and sex. Mechanistic insights and impl
Survodutide, a dual glucagon and GLP-1 receptor agonist, demonstrates significant weight loss and glycemic improvements in adults with obesity and type 2 diabetes, offering promise as a novel therapeutic agent with favorable efficacy and sa
Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, significantly reduces bodyweight and improves glycemic control in adults with obesity and type 2 diabetes, showing promising efficacy and a manageable safety profil
This Swiss retrospective study reveals that while obesity in kidney transplant recipients increases early surgical complications and delayed graft function, it does not affect long-term patient or graft survival, suggesting obesity alone sh
This study demonstrates that elevated BMI and obesity classification do not increase the risk of complications or prolong recovery times following open airway reconstruction surgeries, guiding surgical decision-making in overweight and obes
A 24-year-old obese male presents with incidental liver abnormalities; imaging reveals severe steatohepatitis with unusual features prompting detailed diagnostic evaluation and management strategies.
Most heart failure patients harbor multiple cardiovascular-kidney-metabolic conditions, which independently escalate mortality and readmission risk, especially in HFrEF, underscoring the need for integrated management strategies tailored by
This study reveals that lower serum GLP-1 levels are independently associated with endometrial cancer in obese, non-diabetic women, suggesting its potential as a diagnostic biomarker with high sensitivity and specificity.
This study highlights the limitations of insulin dose-adjusted hemoglobin A1c (IDAA1c) ≤9 in detecting partial remission in US youth with type 1 diabetes, especially those with overweight or obesity, suggesting BMI-specific adjustments impr
Petrelintide, a novel once-weekly human amylin analogue, demonstrates significant bodyweight reduction versus placebo in adults with obesity, with favorable gastrointestinal tolerability, supporting its potential as a long-term obesity ther
In the SELECT trial, baseline clinical factors poorly predicted peak body weight loss with semaglutide, highlighting the role of sex and dosage but underscoring substantial unexplained variability in patient response.
The SELECT trial demonstrates semaglutide’s 20% reduction in major cardiovascular events in adults with obesity and cardiovascular disease. Mediation analysis reveals partial but uncertain roles of weight, inflammation, and glycemic m
This review analyzes global sex disparities in cancer incidence, highlighting modifiable lifestyle and health factors — notably smoking, alcohol, and obesity — as key contributors differing by population context, with implications for tailo
An 8-week trial reveals that intranasal oxytocin increases the free T3/free T4 ratio and correlates with improved mental health-related quality of life in adults with obesity, suggesting thyroid axis modulation as a potential mechanism for
This study reveals distinct left atrial structural and functional changes associated with obesity in atrial fibrillation patients, highlighting a load-related atrial remodeling that may underlie increased risks of atrial fibrillation and he
A clear, clinician-focused summary of the 2025 VA/DoD guideline update: new screening thresholds, streamlined treatment pathways, integration of pharmacotherapy (including GLP‑1 receptor agonists), endoscopic and surgical options, and veter
Physical activity counteracts adiposity-induced immune suppression in lung cancer and non-tumor lungs, restoring antitumor immunity and slowing tumor progression, with implications for lung cancer interception.
